Magnesium substitution in acute ischaemic heart syndromes
M Feldstedt1, S Boesgaard, P Bouchelouche
1Coronary Care Unit, Herlev University Hospital, Denmark.
European Heart Journal
|November 1, 1991
Summary
Intravenous magnesium supplementation did not reduce mortality in patients with acute myocardial infarction. This study found no benefit for magnesium in treating acute ischaemic heart syndromes, and it increased conduction disturbances.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Intravenous magnesium infusion has been proposed to decrease mortality and arrhythmias in acute myocardial infarction patients.
- The efficacy of magnesium in acute ischaemic heart syndromes requires further investigation.
Purpose of the Study:
- To evaluate the effect of intravenous magnesium chloride on mortality and arrhythmias in patients with suspected acute myocardial infarction.
Main Methods:
- A double-blind, placebo-controlled study randomized 298 patients with suspected acute myocardial infarction to receive either magnesium chloride or placebo.
- Infusions were administered immediately upon coronary care unit admission.
- Outcomes including in-hospital mortality and 245-day follow-up mortality were assessed.
Main Results:
- Serum magnesium levels were significantly higher in the magnesium group (P < 0.01).
- No significant difference in in-hospital mortality (12.1% vs. 10.1%) or 245-day mortality was observed between groups.
- Magnesium infusion was associated with a significant increase in atrioventricular conduction disturbances.
Conclusions:
- Intravenous magnesium supplementation does not appear to benefit patients with acute ischaemic heart syndromes.
- Magnesium administration may increase the risk of atrioventricular conduction disturbances in this patient population.
More Related Videos
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
01:14Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626